ROCHESTER, N.Y., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. a clinical-stage biotechnology company pioneering a differentiated approach to treating Cancer and Alzheimer’s disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced the publication in Nature Communications of results from an Emory University and Winship Cancer Institute-sponsored pilot study evaluating pepinemab in patients with metastatic melanoma. The publication represents an important milestone in an almost decade-long scientific partnership between Vaccinex and Winship investigators, focused on advancing the understanding of SEMA4D biology and its potential application in cancer immunotherapy. The findings provide new evidence in human cancer supporting Vaccinex’s strategy of targeting SEMA4D to reshape the tumor immune environment and promote conditions that support recognition of cancer cells and a coordinated antitumor immune response that may complement checkpoint inhibitors and other immunotherapies.